Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria (Dermatology and Therapy, (2025), 10.1007/s13555-025-01596-8)

In the original version of this article, the indication headers were replicated for clarity of Table 2. The old incorrect and the corrected version of the Table 2 are given below. Incorrect version: Table 2 Safety summary Patients, n (%) AD PN CSU Placebo + TCS (N = 315) Dupilumab + TCS (N = 110) Placebo^a (N = 157^b) Dupilumab^a (N = 152^c) Placebo^d (N = 68) Dupilumab^d (N = 70) Any TEAE 266 (84) 97 (88) 80 (51) 91 (59.9) 40 (58.8) 38 (54.3) TESAE 16 (5) 4 (4) 8 (5.1) 7 (4.6) 5 (7.4) 2 (2.9) TEAEs resulting in discontinuation 24 (7.6) 2 (1.8) 3 (1.9) 0 4 (5.9) 2 (2.9) Death 0 0 0 0 1 (1.5) 0 TEAE reported in ≥ 5% of patients Patients with, n (%) Placebo + TCS (n = 315) Dupilumab + TCS (n = 110) Patients with, n (%) Placebo (n = 157^b) Dupilumab (n = 152^c) Patients with, n (%) Placebo (n = 68) Dupilumab (n = 70) Nasopharyngitis^e 61 (19) 25 (23) Headache^e 9 (5.7) 8 (5.3) Chronic spontaneous urticaria^e 6 (8.8) 3 (4.3) Dermatitis atopic^e 144 (46) 20 (18) Neurodermatitis^e 9 (5.7) 3 (2) Angioedema^e 5 (7.4) 1 (1.4) Injection-site reaction^e 24 (8) 16 (15) Injection-site reaction^g 9 (5.7) 6 (3.9) Injection-site reactions^e 2 (2.9) 4 (5.7) Conjunctivitis^e,f 25 (8) 15 (14) Injection-site erythema^e 4 (5.9) 3 (4.3) AD atopic dermatitis, CSU chronic spontaneous urticaria, H1-AH H1 antihistamine, HLT high-level term, MedDRA Medical Dictionary for Regulatory Activities, PN prurigo nodularis, PT preferred term, TCI topical calcineurin inhibitor(s), TCS topical corticosteroid(s), TEAE treatment-emergent adverse event, TESAE treatment-emergent serious adverse event n (%) is number and percentage of patients with at least one TEAE ^aLow-to-medium potency TCS/TCI as background therapy permitted (maintain dose from screening) ^bOne patient included in the PRIME trial was randomized but not exposed to study intervention due to fear of being exposed to coronavirus disease 2019 (COVID-19) ^cOne patient included in the PRIME2 trial was not treated with study intervention ^dPatients remained on their background H1-AH dose throughout the study ^eMedDRA PT ^fNarrow conjunctivitis including MedDRA PTs of conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, and atopic keratoconjunctivitis ^gMedDRA HLT Corrected version: Table 2 Safety summary AD atopic dermatitis, CSU chronic spontaneous urticaria, H1-AH H1 antihistamine, HLT high-level term, MedDRA Medical Dictionary for Regulatory Activities, PN prurigo nodularis, PT preferred term, TCI topical calcineurin inhibitor(s), TCS topical corticosteroid(s), TEAE treatment-emergent adverse event, TESAE treatment-emergent serious adverse event n (%) is number and percentage of patients with at least one TEAE ^aLow-to-medium potency TCS/TCI as background therapy permitted (maintain dose from screening) ^bOne patient included in the PRIME trial was randomized but not exposed to study intervention due to fear of being exposed to coronavirus disease 2019 (COVID-19) ^cOne patient included in the PRIME2 trial was not treated with study intervention ^dPatients remained on their background H1-AH dose throughout the study ^eMedDRA PT ^fNarrow conjunctivitis including MedDRA PTs of conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, and atopic keratoconjunctivitis ^gMedDRA HLT The original article has been corrected.